Found: 24
Select item for more details and to access through your institution.
Low‐dose ponatinib is a good option in chronic myeloid leukemia patients intolerant to previous TKIs.
- Published in:
- American Journal of Hematology, 2020, v. 95, n. 10, p. E260, doi. 10.1002/ajh.25908
- By:
- Publication type:
- Article
Cardiovascular Risk in Polycythemia Vera: Thrombotic Risk and Survival: Can Cytoreductive Therapy Be Useful in Patients with Low-Risk Polycythemia Vera with Cardiovascular Risk Factors?
- Published in:
- Oncology Research & Treatment, 2020, v. 43, n. 10, p. 526, doi. 10.1159/000509376
- By:
- Publication type:
- Article
Cardiovascular Risk in Essential Thrombocythemia and Polycythemia Vera: Thrombotic Risk and Survival.
- Published in:
- Mediterranean Journal of Hematology & Infectious Diseases, 2020, v. 12, n. 1, p. 1, doi. 10.4084/MJHID.2020.008
- By:
- Publication type:
- Article
Ruxolitinib in patients with polycythemia vera resistant and/or intolerant to hydroxyurea: European observational study.
- Published in:
- European Journal of Haematology, 2024, v. 112, n. 3, p. 379, doi. 10.1111/ejh.14124
- By:
- Publication type:
- Article
Age at diagnosis is an important prognostic factor in Philadelphia‐negative Myeloproliferative Neoplasms.
- Published in:
- European Journal of Haematology, 2019, v. 103, n. 2, p. 140, doi. 10.1111/ejh.13266
- By:
- Publication type:
- Article
The Essential Thrombocythemia, Thrombotic Risk Stratification, and Cardiovascular Risk Factors.
- Published in:
- Advances in Hematology, 2020, p. 1, doi. 10.1155/2020/9124821
- By:
- Publication type:
- Article
The Essential Thrombocythemia, Thrombotic Risk Stratification, and Cardiovascular Risk Factors.
- Published in:
- Advances in Hematology, 2020, p. 1, doi. 10.1155/2020/9124821
- By:
- Publication type:
- Article
Clinical Implications of Discordant Early Molecular Responses in CML Patients Treated with Imatinib.
- Published in:
- International Journal of Molecular Sciences, 2019, v. 20, n. 9, p. 2226, doi. 10.3390/ijms20092226
- By:
- Publication type:
- Article
Isolated Nodal TBC Reactivation in a Patient with Post-Thrombocythemia Myelofibrosis Treated with Ruxolitinib: Case Report and Review of the Literature.
- Published in:
- Chemotherapy (0009-3157), 2021, v. 66, n. 3, p. 87, doi. 10.1159/000515430
- By:
- Publication type:
- Article
Management of Ponatinib in Patients with Chronic Myeloid Leukemia with Cardiovascular Risk Factors.
- Published in:
- Chemotherapy (0009-3157), 2019, v. 64, n. 4, p. 205, doi. 10.1159/000504664
- By:
- Publication type:
- Article
The Essential Thrombocythemia in 2020: What We Know and Where We Still Have to Dig Deep.
- Published in:
- Clinical Medicine Insights: Blood Disorders, 2020, p. 1, doi. 10.1177/2634853520978210
- By:
- Publication type:
- Article
The Essential Thrombocythemia in 2020: What We Know and Where We Still Have to Dig Deep.
- Published in:
- Clinical Medicine Insights: Blood Disorders, 2020, v. 13, p. 1, doi. 10.1177/2634853520978210
- By:
- Publication type:
- Article
Cardiovascular risk factor in MPN patients.
- Published in:
- 2020
- By:
- Publication type:
- Letter
Cardiovascular Toxicity in Cancer Patients Treated with Tyrosine Kinase Inhibitors: A Real-World Single-Center Experience.
- Published in:
- Oncology, 2020, v. 98, n. 7, p. 445, doi. 10.1159/000505486
- By:
- Publication type:
- Article
Familial essential thrombocythemia: 6 cases from a mono‐institutional series.
- Published in:
- 2022
- By:
- Publication type:
- Case Study
Late onset of unilateral optic disk edema secondary to treatment with imatinib mesylate.
- Published in:
- Clinical Case Reports, 2017, v. 5, n. 10, p. 1573, doi. 10.1002/ccr3.1137
- By:
- Publication type:
- Article
Triple-Negativity Identifies a Subgroup of Patients with Better Overall Survival in Essential Thrombocythemia.
- Published in:
- Hematology Reports, 2022, v. 14, n. 3, p. 265, doi. 10.3390/hematolrep14030037
- By:
- Publication type:
- Article
Splenomegaly impacts prognosis in essential thrombocythemia and polycythemia vera: A single center study.
- Published in:
- Hematology Reports, 2019, v. 11, n. 4, p. 95, doi. 10.4081/hr.2019.8281
- By:
- Publication type:
- Article
COVID‐19 infection in chronic myeloid leukaemia after one year of the pandemic in Italy. A Campus CML report.
- Published in:
- British Journal of Haematology, 2022, v. 196, n. 3, p. 559, doi. 10.1111/bjh.17890
- By:
- Publication type:
- Article
Cardiovascular Issues in Tyrosine Kinase Inhibitors Treatments for Chronic Myeloid Leukemia: A Review.
- Published in:
- Frontiers in Physiology, 2021, v. 12, p. 1, doi. 10.3389/fphys.2021.675811
- By:
- Publication type:
- Article
An Improved Peer-Review System to Compensate for Scientific Misconduct in Health-Sensitive Topics.
- Published in:
- Public Health Reviews (2107-6952), 2023, p. 1, doi. 10.3389/phrs.2023.1605601
- By:
- Publication type:
- Article
How to read P-values and confidence intervals in public health studies.
- Published in:
- Saudi Journal of Anaesthesia, 2024, v. 18, n. 3, p. 459, doi. 10.4103/sja.sja_128_24
- By:
- Publication type:
- Article
Combination chemotherapy with doxorubicin, bleomycin, and vindesine for AIDS-related Kaposi's sarcoma.
- Published in:
- Cancer (0008543X), 1996, v. 77, n. 10, p. 2117, doi. 10.1002/(SICI)1097-0142(19960515)77:10<2117::AID-CNCR23>3.0.CO;2-X
- By:
- Publication type:
- Article
Antimicrobial prophylaxis in patients with immune thrombocytopenia treated with rituximab: a retrospective multicenter analysis.
- Published in:
- Annals of Hematology, 2021, v. 100, n. 3, p. 653, doi. 10.1007/s00277-021-04438-7
- By:
- Publication type:
- Article